CLL: chronic lymphocytic leukemia PR: pityriasis rosea EGFR: epidermal growth factor receptor PDGFR: platelet-derived growth factor receptor I brutinib, a Bruton tyrosine kinase inhibitor, is a new oral agent approved for the treatment of chronic lymphocytic leukemia (CLL). Ibrutinib is well-tolerated, with the majority of its adverse events within grade 1 or 2 severity. The most common nonhema...

BACKGROUND Pityriasis rosea is an acute inflamatory skin disease that the etiology is unknown but some viral agents like human herpes virus-6 and 7 and drugs are suspected. CASE REPORT A-58-year-old man with chronic hepatitis C was being followed up in our hospital. Pegylated interferon (PEG-IFN) alfa-2b (100 μg per week) and ribavirin (1000 mg/day) was started. In the third month of this tre...

Dear Editor-in-Chief   Lesional histopathological features in pityriasis rosea (PR) are non-specific (1).  Our aim here is to investigate whether a histopathological take-off sign (TOS) is associated with PR.

Pityriasis amiantacea was first described in 1832. The disease may be secondary to any skin condition that primarily affects the scalp, including seborrheic dermatitis. Its pathogenesis remains uncertain. We aim to analyze the epidemiological and clinical profiles of patients with pityriasis amiantacea to better understand treatment responses. We identified seven cases of pityriasis amiantacea ...

Multiple bioengineered agents has been recently developed to attack other parts of the immune/inflammatory system, achieving therapeutic implications for dermatologic diseases. On the other side, each new therapy has the potential for adverse cutaneous reactions. We present herein the first two cases of Gibert's pityriasis rosea occurring during etanercept therapy and discuss possible links bet...